JMS-17-2
JMS-17-2 is a potent and selective antagonist of CX3CR1 with IC50 of 0.32 nM, displays significant selectivity for CX3CR1 over other chemokine receptors such CXCR2, CXCR1, and CXCR4 (IC50>1 uM) ; effectively blocks FKN-induced ERK phosphorylation, also significantly reduces the migration of breast cancer cells in vitro; impairs metastatic seeding and colonization of breast cancer cells, shows long-term anti-tumor effects in vivo.
Product Specifications
CAS Number
1380392-05-1
Product Name Alternative
JMS-17-2 | JMS172 | JMS 17 2 | JMS17-2 | JMS-172
Field of Research
Epigenetics & Chromatin
Purity
>98% (HPLC)
Solubility
In Vitro: DMSO : 25 mg/mL (59.53 mM)
Smiles
O=C1C2=CC=CN2C3=C (C=CC=C3) N1CCCN4CCC (C5=CC=C (Cl) C=C5) CC4
Molecular Formula
C25H26ClN3O
Molecular Weight
419.953
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
5-[3-[4- (4-Chlorophenyl) -1-piperidinyl]propyl]pyrrolo[1,2-a]quinoxalin-4 (5H) -one
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral human RRM2 sgRNA gene knockout kit - Lentiviral human RRM2 sgRNA gene knockout kit (plasmid)
